- Wedbush analyst raised the price target for Intellia Therapeutics (NASDAQ: NTLA), indicating a potential upside.
- The company’s lonvo-z treatment for Hereditary Angioedema (HAE) received FDA Priority Review, setting a target decision date of March 10, 2027.
- Intellia secured a $400 million non-dilutive loan facility to support its goals and potential U.S. launch.
On September 9, 2026, Wedbush analyst David Nierengarten increased the price target for Intellia Therapeutics (NASDAQ: NTLA) to $13.00. Intellia Therapeutics is a clinical-stage biotechnology company focused on developing curative medicines using CRISPR gene-editing technology. At the time, NTLA’s price of $12.64 suggested a potential 2.85% upside to meet the new analyst target.
This positive outlook aligns with growing interest in the genomics sector, which is reshaping healthcare. As highlighted by Zacks Investment Research, NTLA is considered a promising stock in this field. The company is advancing diagnostics and precision medicine, which involves tailoring medical treatment to the individual characteristics of each patient.
A major development for NTLA is the U.S. Food and Drug Administration’s (FDA) acceptance of its Biologics License Application (BLA) for lonvo-z. A BLA is a formal request to market a new biological product. The FDA granted Priority Review, setting a target decision date of March 10, 2027, for the potential one-time treatment for Hereditary Angioedema (HAE).
To support its goals, NTLA secured a loan facility of up to $400 million from OrbiMed. This is a non-dilutive loan, meaning the company raises money without issuing new shares that would reduce the ownership percentage of existing investors. This financing provides flexibility for the potential U.S. launch of lonvo-z.
Currently, NTLA stock trades at $12.62 per share, with a 52-week range between $7.95 and $28.25. The company has a market capitalization of approximately $1.76 billion. Market capitalization is the total value of a company’s shares and is calculated by multiplying the share price by the number of outstanding shares.
